化疗和新型靶向药物在原发性前列腺癌治疗中的作用。
The role of chemotherapy and new targeted agents in the management of primary prostate cancer.
作者信息
Kumar Sanjeev Srinivas, Pacey Simon
机构信息
Department of Oncology, Addenbrookes Hospital, Cambridge, UK.
出版信息
J Clin Urol. 2016 Dec;9(2 Suppl):30-37. doi: 10.1177/2051415816685211. Epub 2016 Dec 1.
Abstract
While early treatment of primary prostate cancer is very effective, the incidence of primary prostate cancer continues to rise and therefore the detection of men with high-risk non-metastatic prostate cancer and their subsequent management is becoming increasingly important. There continues to be no molecularly-targeted or chemotherapeutic options with proven, statistically significant survival benefit in this setting. However, there are indications that further risk stratification using molecular features could potentially help distinguish indolent from aggressive prostate cancer, ultimately providing biological markers that could guide a more personalised approach to therapy selection.
摘要
虽然原发性前列腺癌的早期治疗非常有效，但原发性前列腺癌的发病率仍在持续上升，因此，检测高危非转移性前列腺癌男性患者并对其进行后续管理变得越来越重要。在这种情况下，仍然没有经证实具有统计学显著生存获益的分子靶向或化疗方案。然而，有迹象表明，利用分子特征进行进一步的风险分层可能有助于区分惰性前列腺癌和侵袭性前列腺癌，最终提供能够指导更个性化治疗选择方法的生物标志物。
相似文献
1
The role of chemotherapy and new targeted agents in the management of primary prostate cancer.化疗和新型靶向药物在原发性前列腺癌治疗中的作用。
J Clin Urol. 2016 Dec;9(2 Suppl):30-37. doi: 10.1177/2051415816685211. Epub 2016 Dec 1.
2
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.
3
Advances in the management of high-risk localised and metastatic prostate cancer.高危局限性和转移性前列腺癌的治疗进展。
BJU Int. 2012 Mar;109 Suppl 2:8-13. doi: 10.1111/j.1464-410X.2011.10871.x.
4
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.卡培他滨用于激素受体阳性与激素受体阴性乳腺癌。
Cochrane Database Syst Rev. 2021 May 26;5(5):CD011220. doi: 10.1002/14651858.CD011220.pub2.
5
Primary radical therapy selection in high-risk non-metastatic prostate cancer.高危非转移性前列腺癌的初始根治性治疗选择
Clin Oncol (R Coll Radiol). 2015 Mar;27(3):136-44. doi: 10.1016/j.clon.2014.11.004. Epub 2014 Nov 28.
6
Maximizing outcomes in genitourinary cancers across the treatment continuum.优化泌尿生殖系统癌症治疗全过程的疗效。
BJU Int. 2011 Apr;107 Suppl 2:1-12. doi: 10.1111/j.1464-410X.2010.10035.x.
7
Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer.前列腺癌的靶向前列腺活检和磁共振引导治疗。
Adv Exp Med Biol. 2018;1096:159-184. doi: 10.1007/978-3-319-99286-0_9.
8
Prostate cancer: emerging concepts. Part II.前列腺癌：新观点。第二部分。
Ann Intern Med. 1996 Aug 1;125(3):205-12. doi: 10.7326/0003-4819-125-3-199608010-00009.
9
TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.TOP2A 和 EZH2 可早期检测侵袭性前列腺癌亚群。
Clin Cancer Res. 2017 Nov 15;23(22):7072-7083. doi: 10.1158/1078-0432.CCR-17-0413. Epub 2017 Sep 12.
10
The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.化疗及其他全身治疗在局限性前列腺癌管理中的角色演变
J Urol. 2003 Dec;170(6 Pt 2):S28-32; discussion S33-4. doi: 10.1097/01.ju.0000095356.02647.64.
引用本文的文献
1
Chronic hypoxia-induced slug promotes invasive behavior of prostate cancer cells by activating expression of ephrin-B1.慢性缺氧诱导的 slug 通过激活 Ephrin-B1 的表达促进前列腺癌细胞的侵袭行为。
Cancer Sci. 2018 Oct;109(10):3159-3170. doi: 10.1111/cas.13754. Epub 2018 Aug 29.
2
MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway.微小RNA-204通过靶向沉默信息调节因子1/抑癌基因p53信号通路增强阿霉素处理的前列腺癌细胞的线粒体凋亡。
Oncotarget. 2017 Oct 23;8(57):97313-97322. doi: 10.18632/oncotarget.21960. eCollection 2017 Nov 14.
本文引用的文献
1
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.多西他赛、唑来膦酸或两者联合添加至前列腺癌一线长期激素治疗（STAMPEDE）：一项适应性、多组、多阶段、平台随机对照试验的生存结果
Lancet. 2016 Mar 19;387(10024):1163-77. doi: 10.1016/S0140-6736(15)01037-5. Epub 2015 Dec 21.
2
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.雄激素剥夺疗法 (ADT) 联合多西他赛与单独 ADT 治疗转移性去势抵抗性前列腺癌：转移负担的影响和 GETUG-AFU15 随机 3 期试验的长期生存分析。
Eur Urol. 2016 Aug;70(2):256-62. doi: 10.1016/j.eururo.2015.11.005. Epub 2015 Nov 21.
3
Cell type-specific abundance of 4EBP1 primes prostate cancer sensitivity or resistance to PI3K pathway inhibitors.4EBP1在细胞类型中的特异性丰度决定前列腺癌对PI3K通路抑制剂的敏感性或耐药性。
Sci Signal. 2015 Nov 17;8(403):ra116. doi: 10.1126/scisignal.aad5111.
4
The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.快速雄激素剥夺对人类前列腺癌的早期影响
Eur Urol. 2016 Aug;70(2):214-8. doi: 10.1016/j.eururo.2015.10.042. Epub 2015 Nov 10.
5
The Molecular Taxonomy of Primary Prostate Cancer.原发性前列腺癌的分子分类学
Cell. 2015 Nov 5;163(4):1011-25. doi: 10.1016/j.cell.2015.10.025.
6
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.转移性前列腺癌中的DNA修复缺陷与奥拉帕利
N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.
7
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.拷贝数与转录组学整合为前列腺癌提供风险分层：一项发现与验证队列研究。
EBioMedicine. 2015 Jul 29;2(9):1133-44. doi: 10.1016/j.ebiom.2015.07.017. eCollection 2015 Sep.
8
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
9
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.雄激素剥夺疗法联合多西他赛和雌莫司汀与单独雄激素剥夺疗法治疗高危局限性前列腺癌（GETUG 12）：一项 3 期随机对照临床试验。
Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.
10
The evolutionary history of lethal metastatic prostate cancer.致死性转移性前列腺癌的进化史。
Nature. 2015 Apr 16;520(7547):353-357. doi: 10.1038/nature14347. Epub 2015 Apr 1.
Zotero 插件